← Human Trials & Peer-Reviewed Studies
Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects
Plain-language guide to PMID 28741871 (2017): double-blind randomized controlled trial study of GIP (Gastric Inhibitory Polypeptide) in 51 volunteers.
Key Facts
- PMID
- 28741871
- Journal
- Diabetes, obesity & metabolism
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Portron A et al. (5 authors)
- DOI
- 10.1111/dom.13025
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.
Who Took Part
According to the abstract, 51 volunteers were involved.
The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind GIP (Gastric Inhibitory Polypeptide) study, the assignments were hidden from both participants and investigators until the end.
Some volunteers received a placebo instead of GIP (Gastric Inhibitory Polypeptide), giving a reference point.
Adverse events (AEs) were monitored and drug concentrations, fasting glycaemic variables, vital signs, ECG, antibody formation and routine laboratory variables were assessed.
A meal tolerance test (MTT) was performed at the same time on day -1 (baseline) and day 1.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Half-Life, Healthy Volunteers and Hypoglycemic Agents.
Author keywords: NNC0090-2746, RG7697, RO6811135, dual GIP/GLP-1 agonist and meal tolerance test.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of GIP (Gastric Inhibitory Polypeptide) in 51 volunteers.
Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2017 (Diabetes, obesity & metabolism), a journal based in England.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compound
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.